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which can be submitted to the Agency forToxic Substances and Disease Registry (ATSDR) for continuing medical 
education (CME) credit or continuing education units (CEU). See page 16 for further instructions on how to receive 
these credits.
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□  identify potential environmental and occupational sources of pentachlorophenol exposure
□  Identify evaluation and treatment protocols for pentachlorophenol exposure









Treatment and Management................. 11
Standards and Regulations................... 12
Suggested Reading L is t........................ 13
Sources of Information............................13
Answers to Questions....................... 14-15
Posttest and Credits...............................16
This issue is prepared with the assistance of those who share a common concern for physician education, public 
health, and the environment, including the following organizations: American Academy of Clinical Toxicology, 
American Academy of Family Physicians, American Academy of Pediatrics, American College of Emergency 
Physicians, American College of Occupational and Environmental Medicine, American Medical Association, 
Association of State and Territorial Health Officials, and the Society of Teachers of Family Medicine. Final 
responsibility for the contents and views expressed in this monograph resides with ATSDR.
Agency for Toxic Substances and Disease Registry 
Project Officers: Max Lum, EdD; Donna Orti, MS; and Patricia Poindexter, MPH 
Edited by Teresa Ramsey, MA 
Prepared by DeLima Associates, San Rafael, California, 
under Contract No. 205-90-0817
Case Study
A 63-year-old male with weight loss, fever, dyspnea, and rash
On a hot, humid summer day, a 66-year-oid male with complaints of anorexia, weight loss, flu-like symptoms, 
shortness of breath, and rash is brought to your office by his son. His fever, which began last evening, has been 
recurring since shortly after he moved to this locale to be near his son and grandchildren about 10 months ago. 
While the patient is at his son’s home, in the company of his grandchildren, he seems to improve; yet when the 
patient returns to his home, he becomes ill. The son mentions that his father generally has been withdrawn and 
housebound since he broke his hip a year ago. The patient lives in a log cabin that has only natural ventilation and 
is heated by a wood stove.
Physical examination reveals a well-nourished male, sweating profusely and mildly tachypneic. He exhibits 
confusion and is oriented to person only. His blood pressure is 132/70 sitting, pulse 120/minute and regular, 
respiratory rate 24/minute and shallow without stridor. He has a rectal temperature 104.7T. He has no cough and 
no vomiting or diarrhea. The skin is warm and moist; the mucous membranes are wet. There is a papular 
erythematous rash on the forearms bilaterally and on the neck. There is no skin discoloration, acne, or 
conjunctivitis. There are no focal neurologic findings, including no Kernig’s or Brudzinski’s signs. The lungs are 
clear to auscultation and percussion. There is no costovertebral tenderness. Bowel sounds are normal, and the 
remainder of the abdominal examination is unremarkable. You admit the patient to the hospital.
Further history reveals that the patient is a retired botanist. He had been active and generally well before the 
fall in which he fractured his hip. He is being treated for mild hypertension with a diuretic. There is no other 
significant medical or surgical history. For the past 6 months, the patient has been taking amitriptyline for 
depression as prescribed by his former personal physician, and he has been treating his flu-like symptoms with 
aspirin at the recommended over-the-counter doses. He is using calamine lotion daily on the rash. He admits to 
being generally withdrawn and home-bound but denies any thoughts of suicide.
Initial laboratory values show a serum pH of 7.39, Paco221 and Pao2120 on 2 liters of oxygen. Serum 
electrolytes reveal the following: sodium 131 mEq/L (normal 135-148); potassium 5.1 mEq/L (normal 3.5-5.3); 
chloride 83 mEq/L (normal 95-105); and bicarbonate 21 mEq/L (normal 22-28). The anion gap is 32. Blood urea 
nitrogen is 32 mg/dL (normal 5-20) and creatinine 2.8 mg/dL (normal 0.7-1.5). The urinalysis is normal; urine pH 
is 5.5. Initial white blood count is 11.7 x 103/mm3 (normal 4.5-11 x 103) with 61% neutrophils (normal 60%); the 
spun hematocrit is 47% (normal 42%-52%). Blood salicylate level of 5 mg/dL is within the therapeutic range.
(a) What would you include in this patient’s problem list?
(b) What is the differential diagnosis for this patient?
(c) Is the patient’s condition due to depression? heat stroke?
(d) What further information will you seek to make a diagnosis?




a  In 1987, EPA banned 
pentachlorophenol for all 
nonwood products.
Even “untreated” lumber 
typically is sprayed with or 
dipped in pentachlorophenol 
before it leaves the mill.
Pentachlorophenol (C6CI5OH) and its sodium salt (sodium 
pentachlorophenate) are used as preservatives in the manufacture 
and treatment of a variety of commercial products to prevent decay 
from microorganisms such as fungi, mold, algae, and mosses. Treated 
products include particleboard, textiles, paints, adhesives, leather, 
latex, rubber, pulp, paper, starches, and wood. Pentachlorophenol 
has also been used extensively around the home as an herbicide, 
fungicide, weed and brush killer, disinfectant, and wood-preserving 
compound. Worldwide production estimates range as high as 90 
million pounds; 80% of U.S. consumption is as a wood preservative, 
primarily for telephone and power-line poles.
A common acronym for pentachlorophenol is PCP, which is used 
throughout this document. The street drug phencyclidine (angel dust) 
is also referred to as PCP but has a different pathophysiology and has 
no chemical relationship to pentachlorophenol.
PCP was one of the most widely used biocides in the United States. 
Because of its suspected carcinogenicity, however, in 1987, the 
Environmental Protection Agency (EPA) banned all uses of PCP 
except those for wood products and restricted its availability and use 
to certified applicators. PCP is no longer available to the general 
public, which accounted for only about 3% of the amount used.
Most lumber produced commercially in the United States is still 
treated routinely with sodium pentachlorophenate solution. To control 
fungal growth and sap stain, a typical sawmill will apply a solution of 
the sodium salt to the lumber in a spray box immediately before 
grading and stacking. Pressure-treating wood to thoroughly impreg­
nate it with PCP results in “penta” wood, a product commonly used to 
build outdoor structures such as residential fences, decks, and 
equipment for children’s playgrounds. Penta wood is desirable be­
cause it retains its natural appearance, emanates little odor, and 
accepts paint easily.
Logs for use in the ground typically are treated with PCP and arsenical 
salts as preservatives against microorganisms and termites, then 
coated with creosote, a distillate of coal tar, to form a barrier to 
moisture and to prevent leaching of the PCP and arsenical salts. PCP 
has traditionally been used in log homes. Volatilization from the 
surface of PCP-treated products is estimated at an annual rate of 
roughly 2% of thetotal amount applied. In log homes, this volatilization 
rate has resulted in indoor-air contamination high enough to cause 
PCP-related symptoms in inhabitants.
Due to the extensive use of PCP throughout the United States, it is 
present in air, water, and soil. Contaminated food and water supplies 
are common sources of human intake, although the amounts in-
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gested typically are small. PCP gets into water through wastewater 
discharges from leather tanning and textile factories, municipal 
wastewater treatment facilities, pulp and paper mills, and wood 
treatment plants. Soil contamination occurs as a result of runoff from 
PCP’s past use as an herbicide, leaching from treated wood products 
and spills at industrial facilities and hazardous waste sites. PCP is a 
stable compound, but in water it undergoes photooxidation by sun­
light (half-life 3 to 100 hours depending on pH) and can be 
biotransformed by microorganisms in the soil (half-life 2 to 4 weeks). 
One of the degradation products of PCP is tetrachlorophenol, which 
is also toxic.
CfuiCCe
Additional information for the case study: For years, the patient’s hobbies have included woodworking, 
small-boat building, and organic gardening. Because of his ill health, however, he has not done any of 
these activities for the past several months. He spends most of his time indoors. The patient comments 
that his dog is his only interest now, and the dog seems to get sick when he does.
(1) What are some dues in this case that might lead you to suspect a possible toxic environmental exposure ?
Who's at Risk
The greatest risk of exposure to PCP occurs from occupational 
manufacture and use of the compound, especially in poorly venti­
lated areas. Pest-control applicators who used PCP in indoor 
settings were at great risk from inhalation exposures. Dermal 
exposure occurs primarily to those in trades or professions that 
handle wood, such as carpenters, electric utility-line workers, 
lumber-mill workers, and dock loaders. Sawmill workers are at 
potential risk due to inhalation of contaminated wood dust and 
volatilized PCP when penta wood is cut, especially freshly treated 
wood.
Infants and children are 
predisposed to increased 
PCP exposure by their 
greater surface area-to- 
weight ratios, as well as 
hand-to-mouth and play 
behaviors.
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Living in log homes or other 
structures where PCP has 
been used as a preservative 
increases risk to inhabitants.
PCP continues to leach out of pressure-treated wood for many years. 
Log homes and older dwelling structures where PCP has been used 
as a preservative have been found to have PCP levels in Indoor air 
exceeding those set for the workplace. Chronic exposure of occu­
pants of log cabins and older homes has resulted in PCP toxicity.
Medications and environmental 
conditions that predispose a 
person to hyperthermia 
increase the risk of adverse 
effects to PCP-exposed 
persons.
There is some evidence that children are more susceptible to the 
toxic effects of PCP than adults, and that infants are even more 
susceptible than children, especially by the dermal route of exposure. 
In addition, infants and children may be at increased risk because of 
greater body surface area-to-body weight ratios, higher respiratory 
rates, hand-to-mouth behaviors, and play habits. Neonates exposed 
to PCP in contaminated diapers and bed linens exhibited signs and 
symptoms of serious poisoning.
In the body, PCP acts to uncouple oxidative phosphorylation, result­
ing in hyperthermia. PCP-exposed workers in environments that 
prevent dissipation of heat from the body (e.g., high temperatures 
and high humidity) may be more susceptible to its acute toxic effects. 
Medications that cause dehydration or possess anticholinergic prop­
erties may also increase the susceptibility of exposed persons to 
hyperthermia. Aspirin, which can also uncouple oxidative phospho­
rylation when absorbed in large amounts, may enhance the risk of 
toxicity for PCP-exposed persons. Because PCP is highly protein- 
bound, persons taking medications on a long-term basis that have a 
high affinity for plasma proteins may be at increased risk of PCP- 
induced toxicity. Phenytoin, the anticoagulant warfarin, diuretics 
such as furosemide and ethacrynic acid, and anti-inflammatory 
agents such as ibuprofen and naproxen can compete with PCP for 
protein-binding sites, thereby increasing the level of free PCP that is 
circulating in the blood.
Challmfy





Pulmonary absorption of vapors, aerosols, and dusts are significant 
routes of exposure to PCP. PCP and its sodium salt are also 
absorbed readily via the skin and the gastrointestinal tract.
□  PCP is absorbed readily via 
the skin, respiratory tract, 
and gastrointestinal tract.
Data on distribution of PCP in the body are limited; however, PCP 
is lipophilic, which presumably plays a role in determining its distribu­
tion. In autopsy studies, PCP was detected in the liver, kidneys, and 
brain, with smaller amounts in spleen and adipose tissue.
PCP is highly protein-bound in the blood and is not readily metabo­
lized. In the liver, most PCP is conjugated to a glucuronide; a small 
amount undergoes oxidative dechlorination to tetrachlorohydroqui- 
none (TCH), which has been detected in the urine of persons 
occupationally exposed. Ultimately, about 86% of an absorbed dose 
is excreted in the urine. Biliary excretion occurs in humans, but with 
extensive enterohepatic recirculation, only a small amount of pen­
tachlorophenol (about 4% of an administered oral dose) is detected 
in the feces. Pentachlorophenol is also excreted in the milk of 
lactating humans and animals.
The results of studies conducted in workers suggest that the PCP 
excretion rate differs between acute high-level exposure and chronic 
low-level exposure. Elimination half-lives of about 10 hours were 
found in volunteers undergoing an acute (45-minute) controlled 
inhalation exposure, whereas the elimination half-life in chronically 
exposed workers on vacation was 19 to 20 days. The slower 
elimination of PCP in chronically exposed workers may be a result 
of an established equilibrium between lung, plasma protein, urine, 
and tissue deposits.
□  PCP is excreted largely 
unchanged in the urine; a 
small amount is metabolized 
in the liver.
Physiologic Effects
It is believed that PCP’s high degree of binding to proteins may 
induce conformational changes in enzymes involved in oxidative 
phosphorylation. Oxidative phosphorylation is the process whereby 
electrons generated from various sources such as the tricarboxylic 
acid cycle are transported down the cytochrome system. This 
transport normally results in the consumption of Oz (cellular respira­
tion) and the production of a substantial amount of energy that is 
captured in the production of high-energy phosphate bonds (i.e., 
adenosine triphosphate [ATP] bonds). The energy in these bonds is 
later used during other biochemical reactions.
The acute toxicity of PCP is 





□  PCP toxicity manifests 
primarily as a clinical 
syndrome of hyperthermia 
with associated 
rhabdomyolysis.
□  Neurologic effects from 
PCP exposure are most 
likely the direct result of 
hyperthermia.
□  There is ample evidence of 
hepatotoxicity in 
experimental animals 
exposed to purified PCP.
When the formation of high-energy phosphate bonds is blocked by 
PCP but electron transport continues, then the process of oxidative 
phosphorylation is said to be uncoupled. Uncoupling results in 
cellular energy being released as heat, which produces hyperpyrexia. 
PCP also causes active transport pumps within cell membranes to 
fail, resulting in electrolyte gradient loss, fluid shifts, and even­
tual cell death.
In humans, many of the effects of acute PCP exposure are probably 
secondary to hyperthermia, including neurologic effects and 
rhabdomyolysis. In addition, metabolic acidosis can develop from 
accelerated aerobic metabolism.
Generally, humans are exposed to technical-grade PCP, which 
may be contaminated with dibenzodioxins, dibenzofurans, diphenyl 
ethers, chlorophenoxyphenols, and other chlorinated congeners— 
all of which are suspected to be carcinogenic or known to produce 
other adverse effects. Animal studies with both technical and purified 
PCP have demonstrated that many, but not all, of the toxic effects 
attributed to PCP are actually due to impurities.
Neurologic Effects
Human case reports of PCP exposure suggest that there are central 
and peripheral nervous system effects of toxicity. The neurologic 
effects that manifest after PCP exposure are most likely the result of 
hyperthermia and not a direct effect of PCP on the nervous system. 
Persons acutely exposed to PCP may experience lethargy, tachypnea, 
tachycardia, intermittent delirium, seizures, cerebral edema, focal 
swelling of the myelin sheath, and respiratory distress. Signs indica­
tive of central nervous system toxicity in a 3-year-old girl exposed to 
PCP via the domestic water supply included intermittent delirium, 
fever, and convulsions. No adverse effects on the central or periph­
eral nervous systems have been reported after chronic occupational 
exposure to PCP.
Hepatic Effects
Hepatic toxicity in humans, as manifested by elevated serum SGOT 
(AST) and SGPT (ALT) levels, hepatomegaly, fatty infiltration of the 
liver and centrilobular congestion and degeneration, was seen after 
fatal and nonfatal acute exposures to PCP. However, contaminants 
of technical-grade PCP or exposure to other chemicals may be 
responsible for some of this damage. In experimental animal studies 
that compared the hepatic toxicity of equal doses of technical and 
purified PCP, the effects associated with the purified preparation 
were less severe than those seen with the technical grades in most 
cases. Some ultrastructural changes observed in the mitochondria of 
liver cells of the animals treated with technical-grade PCP were 




In humans and animals, PCP exerts a minor toxic effect on the 
kidneys, producing only mild and transient disturbances. Workers at 
a wood-treatment facility had reduced glomerularfiltration rates and 
mild tubular degeneration, which were reversible when exposure 
ceased. Other evidence of renal dysfunction in humans, such as 
impaired acid-base balance, may be secondary to hyperthermia. In 
animals, little or no consistent difference was seen between techni- 
cal-grade and purified PCP with regard to severity of renal effects.
Carcinogenicity
There is no convincing evidence from epidemiologic studies that 
PCP causes cancer in humans. Case reports suggest a possible 
association between cancer (Hodgkin’s disease, soft-tissue sar­
coma, and acute leukemia) and occupational exposure to technical- 
grade PCP. However, in all of these cases, concurrent exposure to 
other toxic substances may have contributed to the effects. In a 
study by the National Toxicology Program (NTP), pure PCP showed 
oncogenic activity in mice. The International Agency for Research 
on Cancer (I ARC) considers the evidence for carcinogenicity of PCP 
in humans limited, and the evidence for carcinogenicity in animals 
inadequate. The EPA carcinogenic classification for PCP is “prob­
able human carcinogen,” but this classification is currently under 
review.
Other Effects
Chronic exposure to technical-grade PCP has been associated with 
chloracne—an acneiform rash around the eyes, temples, and fore­
head. This skin condition, as well as many other effects of PCP, has 
been attributed to various contaminants in technical-grade PCP, 
particularly dioxins and dibenzofurans. Pemphigus vulgaris and 
urticaria (skin diseases with an immunologic pathophysiology) have 
been reported in several cases of nonoccupational exposures. 
Depigmentation (or vitiligo) and irritant dermatitis have been asso­
ciated with chronic exposure to PCP-containing germicides. Low- 
level chronic exposures to airborne PCP can cause irritation of the 
eyes, nose, throat, and lungs.
Case reports have been published of hemolytic anemia and aplastic 
anemia with subsequent acute leukemia or Hodgkin’s disease. The 
exposures were predominantly dermal exposures to technical- 
grade PCP. The mechanism for these hematologic effects appears 
to be a direct action on blood-forming tissue. The reported anemia 
is unlikely to be caused by uncoupling of oxidative phosphorylation 
because no signs of hyperthermia were observed in these cases.
□  Renal effects from PCP 
exposure are mild 
and transient.
□  Case reports suggest that an 
association exists between 
technical-grade PCP and 
Hodgkin’s disease and soft- 
tissue sarcoma.
□  Other reported effects of 
PCP exposure include skin 
lesions and hematologic 
abnormalities. Most of these 
effects may be due to 
the impurities in technical- 
grade PCP.
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Animals exposed to technical-grade PCP exhibited hematologic 
effects that generally were not observed when the animals were 
administered pure PCP.
There is no evidence that PCP exposure results in human 
embryotoxicity or teratogenicity. In experimental animals, PCP is not 
teratogenic but is embryotoxic and fetotoxic at exposure levels that 
cause maternal toxicity.
Additional information for the case study: Suspecting an environmental toxic exposure, you contact an 
environmental toxicologist at the state health department. After discussing the patient and his symptoms, 
the specialist suggests poisoning caused by an organophosphate pesticide, dinitrophenol, orpentachlo- 
rophenol.
(3) What is the reasoning that leads you to narrow the diagnosis to pentachlorophenol poisoning?
Clinical Evaluation
History and Physical Examination
A thorough environmental 
and occupational history 
may reveal a possible PCP 
exposure in cases in which 
hyperthermia occurs.
The history of a person who has possible PCP exposure should 
include information about other precipitating factors for hyperthermia 
such as age; clothing; environmental temperature and humidity; 
medications with anticholinergic effects, such as phenothiazines, 
antihistamines, and antidepressants; medications that predispose to 
dehydration, such as diuretics; medications or chemicals that un­
couple oxidative phosphorylation, such as salicylates or dinitrophe- 
nols; and medications that interfere competitively with protein bind­
ing, such as warfarin, phenytoin, furosemide, and ibuprofen. A 
thorough environmental and occupational history should be ob­
tained, including information about hobbies or projects such as 
woodworking and gardening. (See Case Studies in Environmental 
Medicine:Taking an Exposure History.)
Because PCP-intoxicated patients may not give the appearance of 
having an elevated temperature, the physical examination must 
include a core body temperature. In addition, blood pressure and 
heart and respiratory rate should be determined. The liver, kidney,
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and central nervous system may be affected by PCP exposure. 
Because exposure to technical-grade PCP has been associated 
with chloracne and other skin conditions, respiratory irritation, and 
blood dyscrasias, the skin, respiratory tract, and blood should be 
evaluated.
Signs and Symptoms 
Acute Exposure
Acute exposure to PCP is associated with hyperthermia, which 
produces a generalized spectrum of toxicity, including anorexia, 
fatigue, thirst, fever, profuse diaphoresis, tachypnea, tachycardia, 
nausea, vomiting, and abdominal pain. In severe poisonings, severe 
muscle spasms and rigidity, as well as seizures, may occur. Hepatic 
enlargement has been reported in adults and infants exposed to 
PCP-containing compounds. Hepatic toxicity has been further mani­
fested in adults by increased SGOT (AST) and SGPT (ALT), fatty 
degeneration, and congestion. Intravascular hemolysis and aplastic 
anemia have been associated with PCP exposure in case reports. 
There is no significant staining of the skin after dermal contact with 
PCP as there is with dinitrophenols, which also cause uncoupling of 
oxidative phosphorylation.
Chronic Exposure
In addition to nonspecific signs and symptoms, such as fever and 
malaise, chronic occupational exposure to high levels of PCP vapor, 
as well as to aerosols, has been associated with conjunctivitis, 
chronic sinusitis, bronchitis, and reduced glomerular filtration and 
tubular function. There is evidence of elevated SGOT and SGPT 
levels in workers after chronic, predominantly dermal, exposure to 
PCP. Most of these conditions are reversible after exposure ceases. 
One group of workers with chronic PCP exposure had a high 
incidence of chloracne, most likely due to PCP contaminants.
Laboratory Tests 
Direct Biologic Indicators
In one study, the general population had average levels of 4 
micrograms of PCP per deciliter (ng/dL) of blood and 5 micrograms 
of PCP per liter (|ig/L) of urine. In studies of workers using PCP or 
PCP-treated materials (e.g., workers involved in construction of log 
homes, repair of telephone lines, custodial care of log cabin muse­
ums, application of pesticides) PCP blood levels ranged from 8.3 to 
5,760 ng/dL and urinary levels ranged from 120 to 10,000 ng/L.
□  Most signs and symptoms of 
acute PCP poisoning are the 
result of hyperthermia.
□  Nonspecific signs and 
symptoms such as fever, 
anorexia, weight 
loss, and fatigue characterize 
chronic PCP exposure.




Residents of log homes treated with PCP preservatives had mean 
levels of 42 (ig/dL in blood and 69 ng/L in urine; PCP blood levels of 
children who resided in log homes were 1.8 times the blood levels of 
their parents.
When monitoring urine levels, relating the PCP concentration to the 
amount of creatinine in the sample (i.e., |xg PCP per gram of 
creatinine [|ig/g creatinine]) corrects for variations in urine concen­
tration. The American Conference of Governmental Industrial Hy- 
gienists (ACGIH) suggests that the biological exposure index (BEI) 
guideline for PCP in the workplace be 1,000 |a.g/g creatinine.
Indirect Biologic Indicators
In PCP poisoning, laboratory evaluation should include tests for 
hepatic and renal dysfunction, electrolyte imbalance, hemolytic 
anemia, and metabolic acidosis. Testing of immune function is not 
warranted in the clinical management of PCP exposure.
Additional information for the case study: You tell the patient and his son that the patient’s symptoms are 
consistent with pentachlorophenol exposure and the source may be the logs of the cabin.
(4) What tests can help you confirm your suspicion?
(5) What further laboratory evaluation is appropriate for the patient, assuming his condition is due to 
pentachlorophenol exposure?
(6) The son asks you if his father’s exposure to pentachlorophenol is increased by using throat lozenges; 





The treatment of pentachlorophenol poisoning is supportive. The 
onset of toxicity may be sudden in persons with significant exposure. 
Thus, it will be necessary to stabilize the patient with maintenance 
of the airway, breathing, and circulation. Patients who have seizures 
will require pharmacotherapy with benzodiazepines. If intubation is 
necessary, general anesthesia or paralysis may be required to 
reduce injury or prevent death during the procedure. Gastric lavage 
will be useful only if the patient has recently ingested the substance. 
Activated charcoal has been shown to bind most phenolic com­
pounds; repeated dosing may be useful in preventing absorption 
and in interrupting enterohepatic recirculation. Cholestyramine resin 
was also used for this purpose in primates, but its effectiveness in 
humans is unknown. Forced diuresis has been proposed as en­
hancing the elimination of PCP; however, the clinical evidence to 
justify this therapy is lacking and volume depletion in patients with 
hyperthermia should be avoided.
After removal from exposure and decontamination, cooling the 
patient is of the utmost importance in the treatment of hyperthermia. 
The patient’s temperature can be reduced with an ice-water bath or 
repeated washes with cool water in front of fans.
Chronic Exposure
Treatment of chronic pentachlorophenol poisoning involves re­
moval from the source of exposure.
(7) What treatment would you recommend for the patient in the case study? What follow-up 





The Occupational Safety and Health Administration (OSH A) has set 
a permissible exposure limit (PEL) for PCP of 0.5 milligrams per 
cubic meter (mg/m3) of air as an 8-hour time-weighted average 
(TWA). OSHA also gives PCP a “skin” designation, which indicates 
the potential for dermal absorption. The National Institute for Occu­
pational Safety and Health (NIOSH) has determined the level im­
mediately dangerous to life and health (IDLH) to be 150 mg/m3 in air.
Environment
In 1984, EPA restricted the use of PCP to wood products. In addition, 
EPA set restrictions on the dioxin levels allowed in pentachlorophe- 
nol products.
The EPA maximum contaminant level (MCL) for PCP in drinking 
water is 1 |o.g/L (1 part per billion [ppb]); the EPA maximum contami­
nant level goal (MCLG) is 0 jxg/L. Several states have guidelines for 
drinking water ranging from 6 to 220 pg/L. The World Health Organi­
zation (WHO) guideline for PCP in drinking water is 10 |ig/L (10 ppb).
The Food and Drug Administration (FDA) lists PCP as safe for use 
as a component of adhesives intended for use in packaging, 
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Department of Health and Human Sen/ices, Public Health Service, 1993.
Environmental Protection Agency. Drinking water criteria document for pentachlorophenol. Washington, DC: US Environmen­
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Sources of Information
More information on the adverse effects of pentachlorophenol and treating cases of exposure can be obtained from 
ATSDR, your state and local health departments, and university medical centers. Case Studies in Environmental 
Medicine: Pentachlorophenol Toxicity is one of a series. To obtain other publications in this series, please use the 
order form on the inside back cover. For clinical inquiries, contact ATSDR, Division of Health Education, Office 
of the Director, at (404) 639-6204.
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Answers to Pretest and Challenge Questions
= A ts d r __________________________________________________
Pretest
Pretest questions begin on page 1.
(a) The patient’s problem list is as follows:
• Fever of undetermined cause (hyperthermia)
• Mildly altered mental status
• History of depression, currently under treatment




(b) The differential diagnosis for a patient who has high fever, tachypnea, and mildly altered mental status must 
include acute overwhelming infections such as pneumonia, meningitis, or urinary tract infection. In addition, 
the patient might be suffering from heat stroke and heat exhaustion (see [c] below), or he may be suffering from 
hyperthermia due to medications or chemical exposure. Heat-related disorders are exacerbated by dehydra­
tion and diuretic use.
(c) No; depression would not cause fever, electrolyte abnormalities, azotemia, or rash. However, the medications 
he is taking for depression may be contributing factors. Heat stroke is unlikely because this condition is usually 
characterized by relatively dry skin and dry mucous membranes, and this patient is suffering from diaphoresis.
(d) Before making a diagnosis, you should explore the conditions in the differential diagnosis. Infection should be 
ruled out early in the management of this case; you may need to perform a lumbar puncture and obtain blood 
and urine cultures. A chest X ray, urinalysis, intravenous pyelogram, and liver function tests may provide 
information to help exclude conditions in the differential diagnosis. Resources to explore chemical poisonings 
can be found at your local or state health department, ATSDR, and the regional poison control center.
Challenge
Challenge questions begin on page 3.
(1) Some clues that indicate a possible environmental exposure, particularly in the home, include the 
following: (1) a temporal relationship between the patient’s onset of symptoms and presence in the 
home, and (2) the simultaneous illness of the patient and his dog. It is not uncommon for illnesses in 
pets to suggest toxic environmental exposures. (See Case Studies in Environmental Medicine: Taking an 
Exposure History.)
(2) Any factors that contribute to hyperthermia could increase the risk for PCP poisoning. Factors for the patient 
in the case study include the following: the age of the patient; environmental conditions (the heat and humidity) 
that prevent heat dissipation; the use of a diuretic (which could enhance dehydration and increase the amount 
of circulating PCP by competing with it for protein-binding sites); the use of a tricyclic antidepressant (which 
has anticholinergic effects); and the use of aspirin (which causes further uncoupling of oxidative phosphory­
lation if taken in excessive amounts).
(3) Organophosphate pesticides, whose mechanism of action is based on acetylcholinesterase inhibition, may 
cause a syndrome of cholinergic excess consisting of salivation, lacrimation, urination, and defecation 
(SLUD). Afull cholinergic syndrome is not seen in this patient. In addition, excessive gastrointestinal symptoms 
and bronchospasm are not present. Patients who have organophosphate pesticide poisoning typically are
14
Pentachlorophenol Toxicity
tachypneic from excess pulmonary secretions and bronchospasm; a high temperature is atypical. 
If necessary, a red blood cell (RBC) count and a plasma cholinesterase level can be obtained. However, even 
if the cholinesterase results are within normal range, tests should be repeated in a few days to determine the 
change in values. (See Case Studies in Environmental Medicine: Cholinesterase-lnhibiting Pesticide Toxicity.)
Dinitrophenol is present in the insecticide Dinoseb.* Like pentachlorophenol, the pathophysiology of dinitro- 
phenol also involves the uncoupling of oxidative phosphorylation; therefore, poisoning due to these two 
chemicals would cause similar symptoms. A thorough and careful history would be necessary to exclude the 
possibility of current contact with the insecticide. Being a botanist by profession and a gardener by hobby, the 
patient should have an awareness of insecticides he has used, especially those used overa long period of time. 
Another feature that distinguishes the two chemicals is the staining property. Yellow stains appear on the skin 
after dermal contact with dinitrophenol; no staining occurs with pentachlorophenol.
(4) To confirm your suspicion of a PCP exposure, you could recommend that the patient’s home be tested for 
airborne levels of PCP. Walls in a room treated with PCP release the chemical into the air, with concentrations 
reaching 1 nanogram per cubic meter (ng/m3) of air on the first day after treatment and 160 ng/m3 on the fourth 
day. PCP is no longer used in the treatment of wood products intended for use in the interior of residences, 
but many log cabins and older homes were built before enforcement of regulations that restricted PCP use.
Biologic tests on the patient could also confirm your suspicion. If the exposure is ongoing, urine and blood levels 
of PCP would be elevated (see Laboratory Tests, page 10).
(5) If the patient has PCP poisoning, further laboratory tests could be performed to evaluate the hepatic, renal, 
and hematologic systems.
(6) Phenol could easily be confused with PCP, especially because they have both been used as disinfectants and 
preservatives. Phenol is found in many over-the-counter and prescription medications (e.g., ointments, ear 
and nose drops, cold-sore lotions, mouthwashes, lozenges, gargles, toothache medications, and analgesic 
rubs) at concentrations of 0.5% to 1.5%. However, the action of phenol and PCP in the body is quite different. 
PCP primarily acts to uncouple oxidative phosphorylation with resultant hyperthermia. Phenol is primarily a 
caustic, causing protein denaturation and coagulation.
(7) After initiating acute care (i.e., establishing an intravenous line, administering antibiotics, and instituting 
cooling treatments), the priority in treating this patient is to prevent further exposure to PCP. This can be 
accomplished by relocating the patient or by decreasing the level of PCP inside the log cabin. Ensuring 
adequate ventilation indoors would help, and application of a barrier wood finish such as clear polyurethane 
to the indoor surfaces of the log cabin would decrease volatilization of the PCP.
* Use of trade names is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services 
or the Public Health Service.
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Posttest and Credits
==A t s d r __________________
Continuing education credit is available to health professionals who use this monograph and complete the 
posttest. The criterion for awarding continuing medical education (CME) credits and continuing education units 
(CEU) is a posttest score of 70% or better.
The Centers for Disease Control and Prevention (CDC) is accredited by the Accreditation Council for Continuing 
Medical Education (ACCME) to sponsor continuing medical education for physicians, and by the International 
Association for Continuing Education and Training (IACET) to sponsor continuing education units for other health 
professionals.
The Agency for Toxic Substances and Disease Registry, in joint sponsorship with CDC, is offering 1 hour of CME 
credit in Category 1 of the Physician's Recognition Award of the American Medical Association and 0.1 hour of 
CEU for other health professionals upon completion of this monograph.
In addition, the series Case Studies in Environmental Medicine has been reviewed and is acceptable for credit 
by the following organizations:
The American Academy of Family Physicians (AAFP). This program has been reviewed and is acceptable for 
1 prescribed hour by the American Academy of Family Physicians. (Term of Approval: beginning January 1992.) 
For specific information, please consult the AAFP Office of Continuing Medical Education.
The American College of Emergency Physicians (ACEP). Approved by the American College of Emergency 
Physicians for one hour per issue of ACEP Category I credit.
The American Osteopathic Association (AOA). AOA has approved this issue for 1 credit hour of Category 
2-B credit.
The American Association of Occupational Health Nurses (AAOHN). AAOHN has approved this program for 
1.0 contact hours. Applicant will receive the assigned code number in the award letter.
The American Board of Industrial Hygiene (ABIH). ABIH has approved this program for 0.5 certification 
maintenance (CM) point per 3 Case Studies. The CM approval number is 2817.
To receive continuing education credit (CME or CEU), complete the Posttest on page 17 in the manner shown in 
the sample question below. Circle all correct answers.





After you have finished the Posttest, please transfer your answers to the answer sheet on the inside back cover 
and complete the evaluation on the lower half of that page. Fold, staple, and mail the inside back cover to 
Continuing Education Coordinator, Agency for Toxic Substances and Disease Registry, Division of Health 
Education, E33, 1600 Clifton Road, Atlanta, GA 30333. Your confidential test score will be returned with an 
indication of where the correct answers can be found in the text. Validation of earned CME credit and CEU will 
also be forwarded to participants, and their names, if requested, will be placed on the mailing list to receive other 




Circle all correct answers. Record your answers on page 19.






2. Which of the following have an increased risk of PCP exposure?
a. electric utility-line workers
b. sawmill workers
c. carpenters
d. occupants of log cabins
e. aircraft mechanics
3. Which of the following statements about PCP are true?
a. It is lipophilic and accumulates in adipose tissue to a large extent.
b. It is eliminated primarily via the feces as a result of biliary excretion.
c. Its principal routes of exposure are inhalation and dermal absorption.
d. It is highly protein bound in the plasma.
e. It undergoes oxidative metabolism in the liver.
4. Which of the following are potential signs and symptoms of acute PCP poisoning?
a. cool, clammy skin
b. hyperthermia
c. SLUD syndrome (salivation, lacrimation, urination, defecation)
d. muscle twitching and tremors
e. metabolic acidosis
5. Which of the following have an important role in the management of acute PCP exposure?
a. decontamination
b. pharmacotherapy for seizures
c. aggressive cooling of the patient
d. Dantrolene
e. Seldane
6. Which of the following may be precipitating factors for hyperthermia secondary to PCP exposure?





7. Which of the following laboratory tests are appropriate for a person chronically exposed to PCP?













= A t s d r
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CASE STUDIES IN ENVIRONMENTAL MEDICINE: PENTACHLOROPHENOL TOXICITY
If you wish CME credits or CEU, please indicate your answers to the Posttest questions on page 17 by circling 
the letters below for the correct answers. Complete the evaluation questionnaire and fill in the information 
requested on the reverse side. Tear off this last page, fold, staple, and mail to Continuing Education Coordinator, 
Agency for Toxic Substances and Disease Registry, Division of Health Education, E33, 1600 Clifton Road, 
Atlanta, GA 30333.
1. a b c d e
2. a b c d e
3. a b c d e
4. a b c d e
5. a b c d e
6. a b c d e
7. a b c d e
8. a b c d e
Evaluation Questionnaire
Please complete the following evaluation by putting a check in the appropriate box.
Yes No Undecided
1. As a result of completing this monograph, I will be able to:
Explain why pentachlorophenol may be an acute and chronic health
health hazard. □ □ □
Describe the factors that may contribute to pentachlorophenol poisoning. □ □ □
Identify potential environmental and occupational sources of 
pentachlorophenol exposure. □ □ □
Identify evaluation and treatment protocols for persons exposed 
to pentachlorophenol. □ □ □
List sources of information on pentachlorophenol. □ □ □
2. I am more likely to ask patients questions regarding possible 
environmental exposures as a result of reading this issue. □ □ □
3. I would recommend this issue to my colleagues. □ □ □
4. I will keep this issue as a reference. □ □ □
Comments:.
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□  CME-AMA □  CME-AAFP □  CME- ACEP □  CME-AOA 
I I CEU □  Contact Hours - AAOHN □  CM - ABIH
Specialty_________________________________________________







Agency for Toxic Substances and Disease Registry 
Division of Health Education, E33 
1600 Clifton Road, NE 
Atlanta, GA 30333
fold here second
Please send me the following Case Studies in Environmental Medicine.
□ Arsenic □ Exposure History □ Radon
a Asbestos □ Gasoline □ Risk Communication
□ Benzene a Jet Fuel □ Reproductive and
a Beryllium a Lead Developmental Haza
a Cadmium a Mercury □ Skin Lesions
a Carbon Tetrachloride □ Methanol □ Stoddard Solvent
□ Chlordane a Methylene Chloride □  Tetrachloroethylene
□ Cholinesterase Inhibitors a Nitrates/Nitrites □ 1,1,1-Trichloroethane
□ Chromium □ Pentachlorophenol □ Trichloroethylene
□ Cyanide a Polyaromatic Hydrocarbons (PAHs) □ Toluene
□ Dioxins a Polychlorinated Biphenyls (PCBs) □ Vinyl Chloride
a Ethylene/Propylene Glycols □ Radiation
ML0993
staple or tape
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The state of knowledge regarding the treatment of patients potentially exposed to 
hazardous substances in the environment is constantly evolving and is often 
uncertain. In this monograph, the Agency for Toxic Substances and Disease 
Registry (ATSDR) has made diligent effort to ensure the accuracy and currency 
of the information presented but makes no claim that the document comprehen­
sively addresses all possible situations related to this substance. This monograph 
is intended as an additional resource forphysicians and other health professionals 
in assessing the condition and managing the treatment of patients potentially 
exposed to hazardous substances. It is not, however, a substitute for the 
professional judgment of a health care provider and must be interpreted in light 
of specific information regarding the patient available to such a professional and 
in conjunction with other sources of authority.
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